Raw CyTOF images associated with Moldoveanu et al. 2022, Science Immunology
Dan Moldoveanu(McGill University Health Centre), Ian R. Watson(McGill University Health Centre), Ari N. Meguerditchian, Béatrice Wang, Daniela F. Quail(McGill University Health Centre), Marine Lingrand, Simon Turcotte(Centre Hospitalier de l’Université de Montréal), Réjean Lapointe(Montreal Neurological Institute and Hospital), Kevin Petrecca(McGill University Health Centre), Sarkis Meterissian(McGill University), Santiago Costantino(Hôpital Maisonneuve-Rosemont), Sinziana Dumitra(Montreal General Hospital), Mathieu Lajoie(McGill University Health Centre), Hamed S. Najafabadi(University of Toronto), Diana Berry(McGill University), Nicholas Bertos(McGill University), Cleber Moraes(McGill University Health Centre), LeeAnn Ramsay(McGill University), Anne‐Marie Mes‐Masson(Centre Hospitalier de l’Université de Montréal), Shivshankari Rajkumar(McGill University Health Centre), Simon Gravel(McGill University), John Stagg(Institute for Research in Immunology and Cancer), Wilson H. Miller(Jewish General Hospital), Kevin Watters(McGill University Health Centre), H. Eric Xu(Harbin Normal University), Catalin Mihalcioiu(McGill University Health Centre), Luke Anderson-Trocmé(McGill Genome Centre), Rached Alkallas(McGill University Health Centre), Amanda W. Lund(New York University), Keith Richardson(McGill University Health Centre), Lucas J. M. Perus(McGill University), Matthew Dankner(McGill University), Sonia V. del Rincón(McGill University), Yuhong Wei(McGill University), Alan Spatz(Jewish General Hospital), Dongmei Zuo(McGill University), May Chergui(McGill University Health Centre), Rahima Jamal(Centre Hospitalier de l’Université de Montréal), Marie‐Christine Guiot(McGill University), Francine Tremblay(Montreal General Hospital), Martin J. Richer(McGill University)
Cited by 1
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
A Review of Cancer Immunotherapy: From the Past, to the Present, to the Future
|Current Oncology|2020|941
The ectonucleotidases <scp>CD</scp>39 and <scp>CD</scp>73: Novel checkpoint inhibitor targets
|Immunological Reviews|2017|901